Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents

US10300120B2 · kind B2 · utility

Assignee

• Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center · US

Inventors

• John Edwards · Rancho Palos Verdes, US
• Ashraf S. Ibrahim · Irvine, US
• Bradley J. Spellberg · Rancho Palos Verdes, US
• Yue Fu · Carson, US
• Scott G. Filler · Rancho Palos Verdes, US
• Michael R. Yeaman · Redondo Beach, US

Key dates

• Filing date: Feb 3, 2016
• Grant date: May 28, 2019
• Expiry date: Feb 3, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue. The Als protein family member can be derived from a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata and Candida parapsilosis and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing Staphylococcus…